INOVIO PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.57 USD | +4.40% |
|
+9.19% | +72.71% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 330 | 1,499 | 1,050 | 389.2 | 139.2 | 273.8 | - | - |
| Enterprise Value (EV) 1 | 330 | 1,499 | 1,050 | 389.2 | 139.2 | 273.8 | 273.8 | 273.8 |
| P/E ratio | -2.73 x | -8.27 x | -3.44 x | -1.33 x | -1 x | -2.74 x | -3.5 x | -28.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 80.3 x | 202 x | 592 x | 37.9 x | 167 x | 453 x | 34.1 x | 2.61 x |
| EV / Revenue | 80.3 x | 202 x | 592 x | 37.9 x | 167 x | 453 x | 34.1 x | 2.61 x |
| EV / EBITDA | - | - | -3,526,960 x | -1,477,500 x | - | - | - | - |
| EV / FCF | - | - | -4.84 x | -1.79 x | -1.12 x | -3.15 x | -3.6 x | -4.8 x |
| FCF Yield | - | - | -20.7% | -55.8% | -89.6% | -31.8% | -27.8% | -20.8% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 8,334 | 14,117 | 17,532 | 20,791 | 22,749 | 25,907 | - | - |
| Reference price 2 | 39.60 | 106.2 | 59.88 | 18.72 | 6.120 | 10.57 | 10.57 | 10.57 |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.112 | 7.411 | 1.775 | 10.26 | 0.832 | 0.6042 | 8.033 | 104.9 |
| EBITDA | - | - | -297.7 | -263.4 | - | - | - | - |
| EBIT 1 | -111.1 | -124.1 | -301.2 | -267.6 | -143.9 | -109.9 | -104.6 | -23.55 |
| Operating Margin | -2,702.1% | -1,674.25% | -16,972.32% | -2,607.35% | -17,300.28% | -18,186.98% | -1,302.36% | -22.45% |
| Earnings before Tax (EBT) 1 | -120.8 | -162.9 | -303.2 | -277.7 | -135.1 | -102.1 | -100.1 | -18.77 |
| Net income 1 | -119.4 | -166.4 | -303.7 | -279.8 | -135.1 | -99.42 | -93.39 | -18.77 |
| Net margin | -2,902.75% | -2,245.39% | -17,109.85% | -2,726.67% | -16,239.87% | -16,454.88% | -1,162.55% | -17.9% |
| EPS 2 | -14.52 | -12.84 | -17.40 | -14.04 | -6.090 | -3.852 | -3.020 | -0.3767 |
| Free Cash Flow 1 | - | - | -216.9 | -217.2 | -124.7 | -87 | -76 | -57 |
| FCF margin | - | - | -12,223.6% | -2,116.34% | -14,986.17% | -14,399.21% | -946.11% | -54.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2917 | 0.8391 | 0.1991 | 0.7844 | 9.154 | 0.1247 | 0.1149 | 0.226 | 0.3884 | 0.1026 | 0.1508 | 0.151 | 0.1512 | 0.1514 |
| EBITDA | -59.09 | -104.4 | - | -103.1 | -34.73 | -54.95 | - | - | - | - | - | - | - | - |
| EBIT 1 | -59.95 | -105.5 | -71.73 | -104.1 | -35.76 | -55.95 | -43.95 | -37.04 | -35.55 | -27.39 | -27.64 | -27.03 | -27.8 | -27.41 |
| Operating Margin | -20,553.02% | -12,573.69% | -36,034.06% | -13,276.05% | -390.61% | -44,875.4% | -38,239.24% | -16,392.04% | -9,152.53% | -26,686.55% | -18,330.24% | -17,901.99% | -18,384.76% | -18,107% |
| Earnings before Tax (EBT) 1 | -60.17 | -106.9 | -79.07 | -108.5 | -37.78 | -54.46 | -40.65 | -35.53 | -33.93 | -25 | -25.79 | -24.96 | -25.96 | -25.43 |
| Net income 1 | -60.17 | -106.9 | -79.07 | -108.5 | -37.78 | -54.46 | -40.65 | -35.53 | -33.93 | -25 | -24.3 | -23.66 | -24.18 | -23.84 |
| Net margin | -20,627.03% | -12,745.21% | -39,721.57% | -13,831.89% | -412.75% | -43,685.84% | -35,365.69% | -15,725.33% | -8,734.68% | -24,358.15% | -16,113.23% | -15,666.23% | -15,994.54% | -15,744.39% |
| EPS 2 | -3.480 | -6.000 | -4.320 | -5.520 | -1.800 | -2.640 | -1.920 | -1.560 | -1.560 | -5.670 | -1.004 | -0.9640 | -0.9560 | -0.9320 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/1/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/1/23 | 5/10/23 | 8/9/23 | 11/9/23 | 3/6/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -217 | -217 | -125 | -87 | -76 | -57 |
| ROE (net income / shareholders' equity) | - | - | -70.6% | -90% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | -12.40 | -10.90 | - | - | - | - |
| Capex | - | - | 1.23 | - | - | - | - | - |
| Capex / Sales | - | - | 69.36% | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/1/21 | 3/1/22 | 3/1/23 | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
10.57
USD
Average target price
19.25
USD
Spread / Average Target
+82.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.71% | 274M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- INO Stock
- Financials Inovio Pharmaceuticals, Inc.
